Aesica Appoints Chris Gowland as Chief Operating Officer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aesica Appoints Chris Gowland as Chief Operating Officer


Aesica, a global contract development and manufacturing organization (CDMO), announced that it has appointed Chris Gowland as Chief Operating Officer. This new position was created to further enhance the company’s operational performance in APIs and formulated product manufacturing services.

As COO, Gowland has overall responsibility for all operating strategy, which includes setting of operational standards and driving continuous improvement across the company’s manufacturing capabilities in API and formulated products.

He will also be responsible for the management of capital expenditure, procurement of materials and services, managing the supply chain, and overseeing capacity expansion across the group to ensure that Aesica meets full customer demand whilst delivering maximum service value.

Gowland is now in charge of the operational performance and general management of all Aesica manufacturing sites including Queenborough and Cramlington in the UK, Monheim and Zwickau in Germany, and Pianezza in Italy.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here